Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.48 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 7/20 | 0.41 |
| ▸ | BRAF | P15056 | 7/20 | 0.41 |
| ▸ | TDP2 | O95551 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10197679 | 0.85 | FAAH (0.44) | ADRB3HDAC8 | |
| SCHEMBL10260016 | 0.84 | FAAH (0.51) | ADRB1ADRB3HDAC8 | |
| SCHEMBL435688 | 0.83 | ADRB3 (0.47) | ADRB1ADRB3HDAC8 | |
| SCHEMBL435888 | 0.82 | FAAH (0.38) | ADRB1ADRB3HDAC8BRAF | |
| SCHEMBL459845 | 0.82 | FAAH (0.49) | ADRB1ADRB3HDAC8 | |
| SCHEMBL459626 | 0.81 | MTNR1A (0.50) | — | |
| SCHEMBL436855 | 0.80 | GHSR (0.46) | ADRB3HDAC8 | |
| SCHEMBL10265076 | 0.80 | ABL1 (0.41) | RAF1BRAF | |
| SCHEMBL461542 | 0.80 | FAAH (0.49) | — | |
| SCHEMBL10265063 | 0.80 | RAF1 (0.41) | HDAC8RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243334-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2012012320-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENIUM PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012012320-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENIUM PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | ADRB1 2185/4885ADRB3 2139/4885HDAC8 13/4885 |
| US-20140243334-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | HDAC6, H1-3, H1-5 | ADRB1 1063/4885ADRB3 1184/4885HDAC8 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.